Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.59 |
| ▸ | CTSB | P07858 | 4/20 | 0.59 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.57 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.55 |
| ▸ | HLA-DRB1 | P01911 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25244713 | 1.00 | CTSL (0.59) | CTSLCTSBCAPN1CTSSCTSK | |
| SCHEMBL25765342 | 0.94 | CTSL (0.56) | CTSLCTSBCAPN1CTSSCTSK | |
| SCHEMBL25289399 | 0.92 | CTSL (0.67) | CTSLCTSBCAPN1CTSSCTSK | |
| SCHEMBL25287897 | 0.92 | CTSL (0.65) | CTSLCTSBCAPN1CTSSCTSK | |
| SCHEMBL25287898 | 0.92 | CTSL (0.65) | CTSLCTSBCAPN1CTSSCTSK | |
| SCHEMBL25242373 | 0.92 | CTSL (0.65) | CTSLCTSBCAPN1CTSSCTSK | |
| SCHEMBL25765339 | 0.92 | CTSL (0.55) | CTSLCTSBCAPN1CTSSCTSK | |
| SCHEMBL25285671 | 0.91 | CTSL (0.69) | CTSLCTSBCAPN1CTSSCTSK | |
| SCHEMBL25285672 | 0.91 | CTSL (0.69) | CTSLCTSBCAPN1CTSSCTSK | |
| SCHEMBL25288107 | 0.90 | CTSL (0.54) | CTSLCTSBCAPN1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212116-A1 | SARS-COV-2 MAIN PROTEASE INHIBITORS | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212116-A1 | SARS-COV-2 MAIN PROTEASE INHIBITORS | ACE2, ACE, TMPRSS2 | CTSL 26/4885CTSB 27/4885CAPN1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.